Frank K. Clyburn's most recent trade in Cencora Inc. was a trade of 557 Common Stock done at an average price of $359.3 . Disclosure was reported to the exchange on March 5, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cencora | Frank K. Clyburn | Director | Grant, award, or other acquisition of securities at price $ 359.28 per share. | 05 Mar 2026 | 557 | 1,724 (0%) | 0% | 359.3 | 200,119 | Common Stock |
| Cencora | Frank K. Clyburn | Director | 30 Sep 2025 | 4 | 1,161 (0%) | 0% | 260.8 | 1,043 | Common Stock | |
| Revolution Medicines Inc | Frank K. Clyburn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2025 | 10,337 | 10,337 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Frank K. Clyburn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2025 | 2,806 | 9,738 (0%) | 0% | 0 | Common Stock | |
| Cencora | Frank K. Clyburn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 789 | 1,157 (0%) | 0% | - | Common Stock | |
| Cencora | Frank K. Clyburn | Director | Grant, award, or other acquisition of securities at price $ 234.27 per share. | 01 Nov 2024 | 368 | 368 (0%) | 0% | 234.3 | 86,211 | Common Stock |
| Revolution Medicines Inc | Frank K. Clyburn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2024 | 26,540 | 26,540 | - | - | Stock Option (Right to Buy) |